6-氨基苯并噻吩-1，1-二氧烷 | 20503-40-6

• 分子结构分类: 有机化合物 - 苯类化合物
• 中文名称: 6-氨基苯并噻吩-1，1-二氧烷
• 中文别名: 6-氨基-1H-1lambda-6-苯并[b]噻吩-1,1-二酮
• 英文名称: 6-aminobenzo[b]thiophene 1,1-dioxide
• 英文别名: 1,1-dioxo-1H-1λ6-benzo[b]thiophen-6-ylamine；1,1-dioxo-1-benzothiophen-6-amine
• CAS: 20503-40-6
• 化学式: C₈H₇NO₂S
• mdl: MFCD00173800
• 分子量: 181.215
• InChiKey: KRUCRVZSHWOMHC-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C
• 沸点：
  467.4±45.0 °C(Predicted)
• 密度：
  1.501±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	6-Amino-1H-1lambda~6~-benzo[b]thiophene-1 1-dione tech Material Safety Data Sheet
Synonym:
CAS:	20503-40-6

Section 1 - Chemical Product MSDS Name:6-Amino-1H-1lambda~6~-benzo[b]thiophene-1 1-dione tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
20503-40-6	6-Amino-1H-1lambda~6~-benzo[b]thiophen		unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 20503-40-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 155 - 156 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7NO2S
Molecular Weight: 181.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 20503-40-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Amino-1H-1lambda~6~-benzo[b]thiophene-1,1-dione - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 20503-40-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 20503-40-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 20503-40-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氨基苯并噻吩-1，1-二氧烷 在 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 4.17h， 生成 N-(3-methoxy-1,1-dioxo-2,3-dihydro-1H-1λ⁶-benzo[b]thiophen-6-yl)acetamide
  参考文献：
  名称：

  [EN] STAT3 INHIBITOR
  [FR] INHIBITEUR DE STAT3

  摘要：

  提供了STAT3抑制剂和治疗炎症或过度增殖疾病（例如癌症）的方法。在某些方面，化合物可用于治疗乳腺癌、头颈癌、肺癌、前列腺癌或胰腺癌。

  公开号：

  WO2014113467A1
• 作为产物：
  描述：

  6-硝基-1H-1lambda~6~-苯并[b]噻吩-1,1-二酮 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 以87%的产率得到6-氨基苯并噻吩-1，1-二氧烷
  参考文献：
  名称：

  苯并[b]噻吩1，1-二氧化物的亲脂性磺酰胺衍生物的合成及其细胞毒活性。

  摘要：

  在寻找具有抗肿瘤活性的新化合物时，我们分析了几种结构修饰对6-苯并[b]噻吩磺酰胺1,1-二氧化物核对肿瘤细胞的细胞毒活性的影响。使用一组人类肿瘤细胞系测得的磺酰胺基团上的亲脂取代基显着提高了细胞毒性活性。当磺酰胺基占据系统的位置5时，仅在细胞毒性上获得了很小的变化。最具活性的化合物是N-4-甲氧基苯基衍生物15，它对HT-29，CCRF-CEM，K-562和MEL-AC细胞的GI（50）值为1-9 nM，而对HTB-200的GI（50）值为200 nM。 54格。为了获得细胞毒性衍生物，似乎需要自由进入杂环系统的3位。

  DOI：

  10.1016/j.bmc.2003.12.012

文献信息

• Pyrazole compounds
  申请人：——

  公开号：US20030060453A1

  公开（公告）日：2003-03-27

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。
• Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3)
  作者：Qiuyao Huang、Yan Zhong、Bingbing Li、Shumin Ouyang、Lin Deng、Jianshan Mo、Shuo Shi、Nan Lv、Ruibo Wu、Peiqing Liu、Wenhao Hu、Xiaolei Zhang、Yuanxiang Wang

  DOI：10.1016/j.ejmech.2021.113525

  日期：2021.10

  of highly potent and selective STAT3 inhibitors, exemplified by compound 39 with the privileged structure of 2-phenylimidazo[1,2-a]pyridine, which selectively inhibits phosphorylation of STAT3 and suppresses subsequent signaling pathway. Moreover, 39 inhibits cell growth, migration and invasion of human triple negative breast cancer (TNBC) cells lines. Consistently, it achieves significant and dose-dependent

  由于其在癌症发生和发展中的重要作用，STAT3 已被证实为有吸引力的抗癌靶点。然而，发现具有类似药物特性的有效且选择性的 STAT3 小分子抑制剂仍然具有挑战性。在这项研究中，通过基于结构的药物发现方法，通过缩合STX-119和SH4-54的特权结构，设计了两个系列的取代 2-苯基喹啉和 2-芳基咪唑并[1,2-a]吡啶。我们的研究发现了许多高效和选择性的 STAT3 抑制剂，例如具有 2-苯基咪唑并[1,2-a]吡啶特权结构的化合物39，它选择性地抑制 STAT3 的磷酸化并抑制随后的信号通路. 而且，39抑制人三阴性乳腺癌 (TNBC) 细胞系的细胞生长、迁移和侵袭。一致地，它在小鼠的细胞系来源和患者来源的异种移植肿瘤模型中实现了显着且剂量依赖性的肿瘤生长抑制。这些结果清楚地表明39是一种高效且选择性的 STAT3 抑制剂。
• Substituted 3-cyanoquinolines
  申请人：American Cyanamid Company

  公开号：US06288082B1

  公开（公告）日：2001-09-11

  This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

  这项发明提供了具有结构的化合物I的公式，其中G1、G2、R1、R4、Z、n和X在规范中定义，或其药用盐，这些化合物可用作抗肿瘤剂，并用于多囊肾病的治疗。
• 一种小分子STAT3抑制剂WZ-2-033及其在 制备治疗乳腺癌和胃癌药物中的应用
  申请人：中山大学

  公开号：CN111658644B

  公开（公告）日：2021-05-14

  本发明属于医药技术领域，公开了一种如下所示的小分子化合物WZ‑2‑033在治疗乳腺癌和胃癌药物中的应用。该化合物能够抑制乳腺癌和胃癌细胞的增殖、克隆形成、迁移和侵袭，并诱导乳腺癌和胃癌细胞的凋亡。该化合物通过影响STAT3信号通路而发挥作用，它能够降低STAT3的磷酸化水平(Y705)、减少STAT3二聚体形成、降低STAT3的DNA结合能力和转录活性，进一步下调STAT3靶基因c‑Myc、Bcl‑xL和Mcl‑1的表达水平，从而抑制STAT3信号的激活，抑制乳腺癌和胃癌细胞的生长。在动物模型中，该化合物能够抑制胃癌细胞移植瘤的生长，具有良好的应用前景。
• 咪唑并吡啶类化合物、包含该化合物的药物组 合物及其制备方法和用途
  申请人：中山大学

  公开号：CN110981868B

  公开（公告）日：2021-08-31

  本发明涉及药物化学和药物治疗学技术领域，具体公开了一类咪唑并[1,2‑a]吡啶类化合物及其药学上可接受的盐或药学上可接受的溶剂合物，此外还公开了其制备方法、包含该化合物的药物组合物和用途，本发明公开的化合物具备抑制STAT3蛋白选择性高、药效强、成药性好、安全等特点，在制备STAT3高表达的细胞异常增殖、形态变化以及运动功能亢进等相关的疾病，以及与血管新生或癌症转移相关的疾病的药物中应用前景好，尤其适用于预防和/或治疗肿瘤生长与转移的药物。